Table VII.
Switching between various anti-TNF agents.
| Clinical end-point | IFX | ETN |
|---|---|---|
| ACR20 response (%) | 61.5 | 28.6 |
| ACR50 response (%) | 30.7 | 14.3 |
| DAS28 | ||
| Mean (± SD) | 4.0 (1.5) | 5.2 (1.6) |
| % change from baseline | −30.8 (28.6) | −16.0 (24.2) |
| Patients with DAS28 score <2.6 (%) | 15.4 | 7.1 |
| Patients with HAQ decrease >0.22 (%) | 61.5 | 14.3 |
| Patients with HAQ decrease >0.40 (%) | 38.5 | 0.0 |
Twenty-eight patients with an inadequate response to ETN were randomised 1:1 to discontinue ETN and receive IFX 3 mg/kg at weeks 0, 2, 6, 14 and 22, or to continue ETN 25 mg twice weekly (patients received background MTX). Efficacy results at week 16. ACR, American College of Rheumatology; DAS28, DAS in 28 joints; HAQ, Health Assessment Questionnaire; IFX, infliximab; ETN, etanercept.